📣 VC round data is live. Check it out!

Cuprina Holdings (Cayman) Valuation Multiples

Discover revenue and EBITDA valuation multiples for Cuprina Holdings (Cayman) and similar public comparables like Momina Krepost, Standard Dental Labs, BioRegenx, Airway Medix and more.

Cuprina Holdings (Cayman) Overview

About Cuprina Holdings (Cayman)

Cuprina Holdings (Cayman) Ltd is a biomedical and biotechnology company that is dedicated to the development and commercialization of products for the management of chronic wounds, as well as operating in the health and beauty sector. It manufactured and distributed a line of medical grade sterile blowfly larvae bio-dressing products marketed under the MEDIFLY brand name, or the MEDIFLY products. The MEDIFLY products are used as a biological debridement tool for chronic wounds, in a procedure known as Maggot Debridement Therapy, or MDT, which is an effective alternative to surgical debridement.


Founded

2023

HQ

Singapore

Employees

14

Financials (FY)

Revenue: $39K
EBITDA: ($4M)

EV

$4M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Cuprina Holdings (Cayman) Financials

Cuprina Holdings (Cayman) reported last fiscal year revenue of $39K and negative EBITDA of ($4M).

In the same fiscal year, Cuprina Holdings (Cayman) generated ($1K) in gross profit, ($4M) in EBITDA losses, and had net loss of ($4M).


Cuprina Holdings (Cayman) P&L

In the most recent fiscal year, Cuprina Holdings (Cayman) reported revenue of $39K and EBITDA of ($4M).

Cuprina Holdings (Cayman) is unprofitable as of last fiscal year, with gross margin of (1%), EBITDA margin of (9137%), and net margin of (9367%).

See analyst estimates for Cuprina Holdings (Cayman)
Last FY202320242025202620272028
Revenue$39K$79K$38K$39K
Gross Profit($1K)$29K($2K)($1K)
Gross Margin(1%)36%(6%)(1%)
EBITDA($4M)($778K)($1M)($4M)
EBITDA Margin(9137%)(986%)(2958%)(9137%)
EBIT Margin(9155%)(1024%)(3066%)(9155%)
Net Profit($4M)($876K)($1M)($4M)
Net Margin(9367%)(1111%)(3230%)(9367%)

Financial data powered by Morningstar, Inc.

Cuprina Holdings (Cayman) Stock Performance

Cuprina Holdings (Cayman) has current market cap of $6M, and enterprise value of $4M.

Market Cap Evolution


Cuprina Holdings (Cayman)'s stock price is $0.27.

Cuprina Holdings (Cayman) share price increased by 6.5% in the last 30 days, and decreased by 98.1% in the last year.

Cuprina Holdings (Cayman) has an EPS (earnings per share) of $-0.17.

See more trading valuation data for Cuprina Holdings (Cayman)
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$4M$6M1.7%6.5%-26.7%-98.1%$-0.17

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Cuprina Holdings (Cayman) Valuation Multiples

Cuprina Holdings (Cayman) trades at 94.8x EV/Revenue multiple, and (1.0x) EV/EBITDA.

See NTM and 2027E valuation multiples for Cuprina Holdings (Cayman)

Cuprina Holdings (Cayman) Financial Valuation Multiples

As of May 20, 2026, Cuprina Holdings (Cayman) has market cap of $6M and EV of $4M.

Cuprina Holdings (Cayman) has a P/E ratio of (1.6x).

Last FY202320242025202620272028
EV/Revenue94.8x47.0x97.9x94.8x
EV/EBITDA(1.0x)(4.8x)(3.3x)(1.0x)
EV/EBIT(1.0x)(4.6x)(3.2x)(1.0x)
EV/Gross Profitn/m129.3xn/mn/m
P/E(1.6x)(6.6x)(4.7x)(1.6x)
EV/FCF(0.5x)(2.9x)(3.8x)(0.5x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Cuprina Holdings (Cayman) Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Cuprina Holdings (Cayman) Margins & Growth Rates

In the most recent fiscal year, Cuprina Holdings (Cayman) reported gross margin of (1%), EBITDA margin of (9137%), and net margin of (9367%).

See estimated margins and future growth rates for Cuprina Holdings (Cayman)

Cuprina Holdings (Cayman) Margins

Last FY20242025202720282029
Gross Margin(1%)(6%)(1%)
EBITDA Margin(9137%)(2958%)(9137%)
EBIT Margin(9155%)(3066%)(9155%)
Net Margin(9367%)(3230%)(9367%)
FCF Margin(18423%)(2603%)(18423%)

Cuprina Holdings (Cayman) Growth Rates

23/2424/2526/2727/2828/29
Revenue Growth(52%)3%
Gross Profit Growth(108%)(79%)
EBITDA Growth44%219%
EBIT Growth44%208%
Net Profit Growth39%199%
FCF Growth(22%)631%

Data powered by FactSet, Inc. and Morningstar, Inc.

Cuprina Holdings (Cayman) Operational KPIs

Cuprina Holdings (Cayman)'s revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.3M for the same period.

Access forward-looking KPIs for Cuprina Holdings (Cayman)
Last FY202320242025202620272028
Revenue per Employee$0.0M
Opex per Employee$0.3M
S&M Expenses to Revenue16%7%13%16%
G&A Expenses to Revenue8792%820%2627%8792%
R&D Expenses to Revenue455%166%499%455%
Opex to Revenue9153%1061%3060%9153%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Cuprina Holdings (Cayman) Competitors

Cuprina Holdings (Cayman) competitors include Momina Krepost, Standard Dental Labs, BioRegenx, Airway Medix, Odinwell, S2Medical, Audientes, Etropal, iZafe Group and Balsm Alofoq.

Most Cuprina Holdings (Cayman) public comparables operate across Medical Supplies.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Momina Krepost5.5x(5.2x)
Standard Dental Labs
BioRegenx
Airway Medix11589.3x13.3x
Odinwell(1.3x)
S2Medical0.3x(0.5x)
Audientes
Etropal1.4x17.9x

This data is available for Pro users. Sign up to see all Cuprina Holdings (Cayman) competitors and their valuation data.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Cuprina Holdings (Cayman)

When was Cuprina Holdings (Cayman) founded?Cuprina Holdings (Cayman) was founded in 2023.
Where is Cuprina Holdings (Cayman) headquartered?Cuprina Holdings (Cayman) is headquartered in Singapore.
How many employees does Cuprina Holdings (Cayman) have?As of today, Cuprina Holdings (Cayman) has over 14 employees.
Who is the CEO of Cuprina Holdings (Cayman)?Cuprina Holdings (Cayman)'s CEO is Yong Qi David Quek.
Is Cuprina Holdings (Cayman) publicly listed?Yes, Cuprina Holdings (Cayman) is a public company listed on Nasdaq.
What is the stock symbol of Cuprina Holdings (Cayman)?Cuprina Holdings (Cayman) trades under CUPR ticker.
When did Cuprina Holdings (Cayman) go public?Cuprina Holdings (Cayman) went public in 2025.
Who are competitors of Cuprina Holdings (Cayman)?Cuprina Holdings (Cayman) main competitors include Momina Krepost, Standard Dental Labs, BioRegenx, Airway Medix, Odinwell, S2Medical, Audientes, Etropal, iZafe Group, Balsm Alofoq.
What is the current market cap of Cuprina Holdings (Cayman)?Cuprina Holdings (Cayman)'s current market cap is $6M.
What is the current revenue of Cuprina Holdings (Cayman)?Cuprina Holdings (Cayman)'s last fiscal year revenue is $39K.
What is the current EV/Revenue multiple of Cuprina Holdings (Cayman)?Current revenue multiple of Cuprina Holdings (Cayman) is 94.8x.
Is Cuprina Holdings (Cayman) profitable?No, Cuprina Holdings (Cayman) is not profitable.
How many companies Cuprina Holdings (Cayman) has acquired to date?Cuprina Holdings (Cayman) hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Cuprina Holdings (Cayman) has invested to date?Cuprina Holdings (Cayman) hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Cuprina Holdings (Cayman)

Lists including Cuprina Holdings (Cayman)

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial